Equities Analysts Offer Predictions for ADIL FY2024 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Litchfield Hills Research boosted their FY2024 EPS estimates for Adial Pharmaceuticals in a report released on Thursday, November 21st. Litchfield Hills Research analyst T. O’neill now anticipates that the company will post earnings per share of ($1.31) for the year, up from their prior forecast of ($1.82). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.79) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.33) EPS.

Several other brokerages have also issued reports on ADIL. Rodman & Renshaw started coverage on Adial Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $8.00 price target on the stock. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Adial Pharmaceuticals Trading Down 1.0 %

Shares of ADIL opened at $1.01 on Monday. The business’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.11. Adial Pharmaceuticals has a 52 week low of $0.77 and a 52 week high of $4.17.

Institutional Investors Weigh In On Adial Pharmaceuticals

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. 16.41% of the stock is currently owned by institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.